Nipah virus (NiV) is a highly pathogenic zoonotic virus with mortality rates between 21% and 82% that causes recurrent epidemics in South and Southeast Asia. A vaccine based on recombinant soluble Hendra virus glycoprotein G (HeV-sG-V) has demonstrated safety and the ability to induce an immune response in adults in phase 1 and 2 clinical trials. This vaccine provides cross-protection against both Nipah and Hendra viruses and has been effective after just one dose in preclinical animal studies, including nonhuman primates. Clinical trials are underway in various countries, including Bangladesh, where the virus regularly occurs. The immune response is measured by the level of neutralizing antibodies, with higher titers correlating with complete protection against disease. The development of the vaccine is supported by organizations such as CEPI, and the vaccine uses a platform similar to that used for the COVID-19 vaccine. The results of the phase 2 clinical trial are expected and may lead to the approval of the vaccine to protect the population in outbreaks[1][2][3][4][5][6][7].